CN110446511B - 短效的基于肝素的抗凝血剂化合物和方法 - Google Patents

短效的基于肝素的抗凝血剂化合物和方法 Download PDF

Info

Publication number
CN110446511B
CN110446511B CN201880020095.XA CN201880020095A CN110446511B CN 110446511 B CN110446511 B CN 110446511B CN 201880020095 A CN201880020095 A CN 201880020095A CN 110446511 B CN110446511 B CN 110446511B
Authority
CN
China
Prior art keywords
ost
idoa2s
heparin
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880020095.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110446511A (zh
Inventor
刘健
王章杰
谢柏宏
徐咏梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Priority to CN202310342719.2A priority Critical patent/CN116622006B/zh
Publication of CN110446511A publication Critical patent/CN110446511A/zh
Application granted granted Critical
Publication of CN110446511B publication Critical patent/CN110446511B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201880020095.XA 2017-03-10 2018-03-12 短效的基于肝素的抗凝血剂化合物和方法 Active CN110446511B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310342719.2A CN116622006B (zh) 2017-03-10 2018-03-12 短效的基于肝素的抗凝血剂化合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469643P 2017-03-10 2017-03-10
US62/469,643 2017-03-10
PCT/US2018/021986 WO2018165656A1 (en) 2017-03-10 2018-03-12 Short-acting heparin-based anticoagulant compounds and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310342719.2A Division CN116622006B (zh) 2017-03-10 2018-03-12 短效的基于肝素的抗凝血剂化合物和方法

Publications (2)

Publication Number Publication Date
CN110446511A CN110446511A (zh) 2019-11-12
CN110446511B true CN110446511B (zh) 2024-04-02

Family

ID=63449042

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880020095.XA Active CN110446511B (zh) 2017-03-10 2018-03-12 短效的基于肝素的抗凝血剂化合物和方法
CN202310342719.2A Active CN116622006B (zh) 2017-03-10 2018-03-12 短效的基于肝素的抗凝血剂化合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310342719.2A Active CN116622006B (zh) 2017-03-10 2018-03-12 短效的基于肝素的抗凝血剂化合物和方法

Country Status (5)

Country Link
US (2) US11903963B2 (enExample)
EP (1) EP3579897A4 (enExample)
JP (2) JP7330893B2 (enExample)
CN (2) CN110446511B (enExample)
WO (1) WO2018165656A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
EP3691653B1 (en) 2017-11-03 2025-03-12 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
EP3810152A4 (en) 2018-06-20 2022-04-27 The University of North Carolina at Chapel Hill CELL PROTECTION METHODS AND COMPOSITIONS
MX2021008479A (es) 2019-01-15 2021-10-13 Optimvia Llc Enzimas dependientes de aril sulfato modificadas por ingenieria genetica.
CA3144968A1 (en) 2019-07-09 2021-01-14 Optimvia Llc Methods for synthesizing anticoagulant polysaccharides
JP2023501568A (ja) * 2019-11-13 2023-01-18 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 肝虚血再灌流障害におけるヘパラン硫酸（ｈｓ）オリゴ糖の効果
US20250154290A1 (en) * 2022-02-17 2025-05-15 Kyushu University, National University Corporation Recombinant heparin-like substance and method for producing the same
CN115417937B (zh) * 2022-08-12 2023-06-06 山东大学 一种含双抗凝血酶结合序列的肝素十二糖及其制备方法与应用
CN116120484B (zh) * 2022-09-01 2024-11-08 山东大学 一种抗凝血肝素寡糖苯联二聚体及其制备方法与应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IT1232939B (it) 1987-11-06 1992-03-10 Opocrin Spa Eparan solfato caratterizzato da elevata attivita' antitrombotica, elevata biodisponibilita', assenza di attivita' anticoagulante; suo processo di estrazione da organi e da tessuti e relative composizioni farmaceutiche
US4865870A (en) 1988-07-07 1989-09-12 Becton, Dickinson And Company Method for rendering a substrate surface antithrombogenic
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US5378829A (en) 1990-04-23 1995-01-03 Akzo N.V. Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type
WO1993005167A1 (en) 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses
IT1260137B (it) 1992-04-17 1996-03-28 Alfa Wassermann Spa Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
JP3818676B2 (ja) 1994-07-22 2006-09-06 生化学工業株式会社 ヘパラン硫酸６−ｏ−硫酸基転移酵素
IT1271057B (it) 1994-11-04 1997-05-26 Inalco Spa Polisaccaridi aventi un elevato contenuto di acido iduronico
JP3672359B2 (ja) 1995-07-24 2005-07-20 生化学工業株式会社 ヘパラン硫酸 ２−ｏ−硫酸基転移酵素
JP3713276B2 (ja) 1995-09-29 2005-11-09 バイオマリン ファーマシューティカル インコーポレイテッド 炎症反応の軽減のためのヘパリナーゼの使用
US5935824A (en) 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6861254B1 (en) 1997-10-24 2005-03-01 Massachusetts Institute Of Technology Heparan sulfate D-glucosaminyl 3-O-sulfotransferases, and uses therefor
US8088604B2 (en) 1998-04-02 2012-01-03 The Board Of Regents Of The University Of Oklahoma Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US6255088B1 (en) 1999-05-11 2001-07-03 The Scripps Research Institute Enzymatic sulfation of biomolecules
US6977248B1 (en) * 1999-08-25 2005-12-20 Massachusetts Institute Of Technology Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
US7101859B2 (en) 2000-01-10 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
CA2698561C (en) 2000-07-07 2012-07-10 Seikagaku Corporation Hyaluronic acid oligosaccharide fractions and drugs containing the same
CA2441984A1 (en) 2001-03-28 2002-10-10 Massachusetts Institute Of Technology Methods of 6-o-sulfating polysaccharides and 6-o-sulfated polysaccharide preparations
WO2002089742A2 (en) 2001-05-08 2002-11-14 The Board Of Regents Of The University Of Oklahoma Heparin/heparosan synthase and methods of making and using same
PT1401853E (pt) 2001-05-25 2010-12-07 Univ Duke Modulador de oligonucleotídeos
WO2003018598A2 (en) 2001-08-30 2003-03-06 University College Dublin Monosaccharide derivatives
US7531338B2 (en) * 2002-07-05 2009-05-12 The University Of North Carolina At Chapel Hill Purified and isolated heparan sulfate 3-O-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
GB0216861D0 (en) 2002-07-19 2002-08-28 Univ Birmingham Saccharide libraries
WO2004017910A2 (en) 2002-08-23 2004-03-04 Neose Technologies, Inc. Total synthesis of heparin
WO2005014619A2 (en) 2003-03-28 2005-02-17 Thomas Jefferson University Heparin-binding peptides and uses thereof
US20040259142A1 (en) 2003-06-04 2004-12-23 Imperial College Innovations Limited Products and methods
EP1529785B1 (en) 2003-10-24 2011-03-16 3M Innovative Properties Company Aqueous dispersions of polytetrafluoroethylene particles
US7655445B2 (en) 2003-11-12 2010-02-02 Massachusetts Institute Of Technology Methods for synthesis of sulfated saccharides
WO2005118609A2 (en) 2004-05-26 2005-12-15 California Institute Of Technology Small molecule stimulators of neuronal growth
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US20060229276A1 (en) 2004-07-28 2006-10-12 Magnus Hook Use of glycosoaminoglycans for the prevention and treatment of sepsis
US20090197308A1 (en) * 2005-05-12 2009-08-06 Jian Liu Enzymatic synthesis of sulfated polysaccharides
WO2007023867A1 (ja) 2005-08-24 2007-03-01 Seikagaku Corporation 新規コンドロイチン画分製造方法
EP2447285A3 (en) 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
WO2009014715A2 (en) 2007-07-23 2009-01-29 The University Of North Carolina At Chapel Hill Enzymatic synthesis of sulfated polysaccharides without iduronic acid residues
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
US20110009361A1 (en) 2007-12-21 2011-01-13 Glycan Biosciences Pty Ltd Design and selection of medicaments that modulate the function and activity of interleukin 13
US8455439B2 (en) 2008-11-14 2013-06-04 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
WO2010087207A1 (ja) 2009-02-02 2010-08-05 大塚化学株式会社 低分子量多硫酸化ヒアルロン酸誘導体及びこれを含有する医薬
SG175133A1 (en) 2009-04-09 2011-12-29 Univ North Carolina Methods of treating edema related to ischemia-reperfusion
US20110054236A1 (en) 2009-08-25 2011-03-03 The Regents Of The University Of Michigan Compositions and methods for targeting tumors
WO2011038047A1 (en) 2009-09-23 2011-03-31 Momenta Pharmaceuticals, Inc. Methods of treatment with a low molecular weight heparin composition
NZ611316A (en) 2010-12-01 2014-12-24 Univ Australian Histone inhibition
US11203772B2 (en) 2010-12-23 2021-12-21 The University Of North Carolina At Chapel Hill Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins
WO2012116048A1 (en) 2011-02-22 2012-08-30 Rensselaer Polytechnic Institute Single step heparosan n-deacetylation and depolymerization for making bioengineered heparin
US8519189B2 (en) 2011-06-01 2013-08-27 University Of British Columbia Polymers for reversing heparin-based anticoagulation
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
EP3011043B1 (en) * 2013-06-17 2022-05-11 The University of North Carolina At Chapel Hill Reversible heparin molecules
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
EP3691653B1 (en) 2017-11-03 2025-03-12 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
EP3810152A4 (en) 2018-06-20 2022-04-27 The University of North Carolina at Chapel Hill CELL PROTECTION METHODS AND COMPOSITIONS
JP2023501568A (ja) 2019-11-13 2023-01-18 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 肝虚血再灌流障害におけるヘパラン硫酸（ｈｓ）オリゴ糖の効果
JP7670561B2 (ja) 2021-06-28 2025-04-30 日本航空電子工業株式会社 コネクタ

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Chemoenzymatic synthesis of Homogeneous Ultralow Molecular Weight Heparins";Y. Xu等;《SCIENCE》;20111027;498-501 *
"Using a 3-O-Sulfated Heparin Octasaccharide To Inhibit the Entry of Herpes Simplex Virus Type 1";Ronald Copeland等;《Biochemistry》;20080506;5774–5783 *

Also Published As

Publication number Publication date
WO2018165656A1 (en) 2018-09-13
JP7702454B2 (ja) 2025-07-03
US11903963B2 (en) 2024-02-20
CN110446511A (zh) 2019-11-12
JP2023166387A (ja) 2023-11-21
CN116622006A (zh) 2023-08-22
JP2020510119A (ja) 2020-04-02
CN116622006B (zh) 2025-05-30
EP3579897A1 (en) 2019-12-18
US20210137967A1 (en) 2021-05-13
US20240066048A1 (en) 2024-02-29
JP7330893B2 (ja) 2023-08-22
EP3579897A4 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
CN110446511B (zh) 短效的基于肝素的抗凝血剂化合物和方法
Noti et al. Chemical approaches to define the structure-activity relationship of heparin-like glycosaminoglycans
Linhardt 2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity
Peterson et al. Design of biologically active heparan sulfate and heparin using an enzyme-based approach
JP6670235B2 (ja) 可逆的ヘパリン分子、その製法及びその使用方法
JP4861596B2 (ja) ヒアルロン酸オリゴ糖画分およびそれを含む医薬
Li et al. Enzymatic synthesis of chondroitin sulfate E to attenuate bacteria lipopolysaccharide-induced organ damage
EP2025687A1 (en) Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby
TW200846014A (en) Low molecular weight heparins comprising at least one covalent bond with biotin or a biotin derivative, preparation process therefor and use thereof
Schenauer et al. Heparan sulfate separation, sequencing, and isomeric differentiation: ion mobility spectrometry reveals specific iduronic and glucuronic acid-containing hexasaccharides
Ikeda et al. Synthesis and biological activities of a library of glycosaminoglycans mimetic oligosaccharides
BR112013027389B1 (pt) Processo para o preparo de sal sódico de sulfato de condroitina
US12280072B2 (en) Oligosaccharide compound for inhibiting intrinsic coagulation factor X-enzyme complex, and preparation method therefor and uses thereof
US20190002596A1 (en) Sulfated heparin oligosaccharide and preparation method and application thereof
KR102007554B1 (ko) N-탈황화된 글리코스아미노글리칸 유도체 및 약물로서의 용도
Ha et al. Characterization of heparan sulfate from the unossified antler of Cervus elaphus
Hu et al. Probing cleavage promiscuity of heparinase III towards chemoenzymatically synthetic heparan sulfate oligosaccharides
TW200902036A (en) Heparins comprising at least one covalent bond with biotin or a biotin derivative, preparation process therefor and use thereof
JPH05503506A (ja) 芳香族ポリマーを含む薬学的組成物及びそれを用いる治療法
Zhang et al. Interactions between nattokinase and heparin/GAGs
JP4528898B2 (ja) ケモカイン受容体ｃｃｒ１０の発現誘導剤
O'Leary Chemical and Enzymatic Methods for the Analysis and Synthesis of Heparin and Heparan Sulfate
US20050043273A1 (en) Compositions and methods for inhibiting slit protein and glypican interactions
Zhang et al. Heparin mimetics as tools for modulation of biology and therapy
RU2760706C2 (ru) Биосинтетический гепарин

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
GR01 Patent grant
GR01 Patent grant